Oxford Nanopore said on Thursday that it’s planning to list on the London Stock Exchange.
The DNA-sequencing company, which provides rapid Covid-19 tests, said the offering will comprise new and existing shares, and that it expects to list a stake of at least 25%.

It said proceeds from the IPO will be used to continue to invest in growth opportunities, “driven by the ambition to be a global company that enables the analysis of anything by anyone, anywhere”.

The company said there is a substantial global market opportunity for its “unique offering” and business model. It noted that DNA/RNA sequencing represents an estimated $5.7bn market in 2021, with an estimated compound annual growth rate of 18% between 2020 and 2023.

Chief executive officer Dr. Gordon Sanghera said: “We believe Oxford Nanopore is ideally suited to both disrupt existing markets and create entirely new ones. An IPO will be a step on the journey to make our vision a reality, supporting our ambitious growth plans and enhancing our ability to innovate and grow.”

Related articles

Ryanair passenger numbers jump 9% in December

Ryanair passenger numbers jump 9% in December

(Sharecast News) - Budget airline Ryanair reported a 9% jump in December passenger numbers on Wednesday. Traffic rose to 12.54 million from 11.52m in the same month a year earlier, while the load factor - which gauges how full the planes are - ticked down to 91% from...

Wizz Are passenger numbers soar in December

Wizz Are passenger numbers soar in December

(Sharecast News) - Hungary-based budget airline Wizz Air reported a strong rise in December passenger numbers as demand continued to rebound from the Covid pandemic. The company on Wednesday said it carried 4,964,857 passengers, an 18.8% increase year on year. For the...

Trending stories

Join our mailing list

Subscribe to our mailing list to receive regular updates!

x